A Multi-center, International Prospective Follow up Study

Stopped early

Conditions studied: Benign Prostatic Hyperplasia (BPH)

In brief

The study objective is to assess the safety and efficacy of iTind three to five years following treatment.

Key facts

Study ID

NCT04579913

Run by

Medi-Tate Ltd.

People needed

17

Starts

2020-12-21

Expected to finish

2021-04-22

Last updated by the study team

2021-04-29

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Subject signed informed consent form (ICF)
• Subject who had participated in the MT-03 study in the iTind arm
• Subject able to comply with the study protocol.

You may not qualify if…

• Any anatomical or physiological condition that in the opinion of the investigator likely to impede successful completion of the study
• Patients that are known to have had undergone an alternative surgical procedure for BPH during MT-03 study.

Where it is running

• Clinical Research Center of Florida — Pompano Beach, Florida, United States
• Manhattan Medical research — Manhattan, New York, United States
• Premier Urology Group — New York, New York, United States
• Lenox Hill Hospital — New York, New York, United States
• Toronto — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.